• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Bhatt Elizabeth

    6/13/24 6:15:27 PM ET
    $EFTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EFTR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Bhatt Elizabeth

    (Last) (First) (Middle)
    C/O EFFECTOR THERAPEUTICS, INC.
    142 NORTH CEDROS AVENUE, SUITE B

    (Street)
    SOLANA BEACH CA 92075

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    eFFECTOR Therapeutics, Inc. [ EFTR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/13/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $1.38 06/13/2024 A 800 (1) 06/12/2034 Common Stock 800 $0 800 D
    Explanation of Responses:
    1. The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest in full on the earlier to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date.
    /s/ Michael Byrnes, Attorney-in-Fact for Elizabeth Bhatt 06/13/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $EFTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EFTR

    DatePrice TargetRatingAnalyst
    1/25/2022$20.00 → $16.00Outperform
    Credit Suisse
    1/25/2022$20.00 → $6.20Buy → Hold
    Stifel
    1/25/2022$33.00 → $8.00Market Outperform
    JMP Securities
    11/9/2021$20.00Hold → Buy
    Stifel
    10/12/2021$20.00Outperform
    Credit Suisse
    10/4/2021$20.00Buy
    Mizuho
    9/21/2021$33.00Market Outperform
    JMP Securities
    9/20/2021$20.00Hold
    Stifel
    More analyst ratings

    $EFTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by eFFECTOR Therapeutics Inc. (Amendment)

      SC 13D/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      5/13/24 4:05:28 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by eFFECTOR Therapeutics Inc. (Amendment)

      SC 13G/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      2/14/24 3:48:31 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by eFFECTOR Therapeutics Inc. (Amendment)

      SC 13G/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      2/14/24 9:48:49 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EFTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $EFTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq

      SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a d

      6/24/24 7:00:00 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

      SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+) endometrial cancer and low grade serous ovarian cancer at the Dana-Farber Cancer Institute (DFCI) under the direction of Panagiotis Konstantinopoulos, M.D., Ph.D., Director of Translational Research and attending oncologist in the Division of Gynecologic Oncology at

      5/20/24 8:30:00 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

      Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. "We had a productive first quarter marked by continued progress in the zotatifin program, including successful completion of the

      5/9/24 4:01:00 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse reiterated coverage on eFFECTOR Therapeutics with a new price target

      Credit Suisse reiterated coverage of eFFECTOR Therapeutics with a rating of Outperform and set a new price target of $16.00 from $20.00 previously

      1/25/22 8:03:42 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • eFFECTOR Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded eFFECTOR Therapeutics from Buy to Hold and set a new price target of $6.20 from $20.00 previously

      1/25/22 7:56:26 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on eFFECTOR Therapeutics with a new price target

      JMP Securities reiterated coverage of eFFECTOR Therapeutics with a rating of Market Outperform and set a new price target of $8.00 from $33.00 previously

      1/25/22 6:37:05 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EFTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Loewy Caroline M

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      6/13/24 6:45:57 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Klencke Barbara

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      6/13/24 6:35:38 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ehrlich Christopher B

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      6/13/24 6:25:33 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EFTR
    SEC Filings

    See more
    • SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.

      EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)

      8/2/24 12:15:03 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.

      EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)

      8/2/24 12:15:10 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.

      EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)

      8/2/24 12:15:06 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EFTR
    Leadership Updates

    Live Leadership Updates

    See more
    • eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq

      SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a d

      6/24/24 7:00:00 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors

      SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board's Audit Committee. Concurrent with Ms. Loewy's appointment, current Board member John Smither has resigned from the Board. "We are tremendously fortunate to welcome Caroline given her extensive experience as an executive and board member at multiple biopharmaceutical companies," remarked Steve Worland, Ph.D., president and chief executive office

      9/11/23 8:00:00 AM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      - Key executive appointments: Douglas Warner, M.D., as CMO & Mayank Gandhi, M.D., as CBO – - Cohort treating ER+ breast cancer with combination of zotatifin, fulvestrant and abemaciclib has been expanded from 7 patients to 18 patients - - Initiated dosing and completed enrollment in second cohort of Phase 1b clinical trial of zotatifin for the treatment of COVID-19 - SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended

      11/7/22 4:00:00 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EFTR
    Financials

    Live finance-specific insights

    See more
    • eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting

      Partial responses observed in 5 of 19 (26%) evaluable patients treated with zotatifin 0.07 mg/kg combined with fulvestrant and abemaciclib (ZFA triplet) in heavily pretreated populationPartial response observed in 1 of 3 (33%) patients treated with zotatifin 0.1 mg/kg combined with fulvestrant (ZF doublet)Both combinations were generally well tolerated with large majority of adverse events Grade 1 or 2Company will host a virtual investor call on June 4, 2023, to discuss the data and clinical progress SOLANA BEACH and REDWOOD CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("

      5/25/23 4:50:54 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Updated data from two fully enrolled Phase 2 expansion cohorts testing zotatifin-based combinations in estrogen receptor-positive (ER+) Metastatic Breast Cancer to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 on June 4, 2023 Company will host conference call to discuss results and further development of zotatifin during ASCO Annual Meeting 2023 Zotatifin is being evaluated in patients with ER+, human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a pre-operative setting through clinical collaboration with Jennifer Caswell-Jin, M.D., Assistant Professor of Medicine at Stanford Medicine SOLANA BEACH and REDWOOD CITY, Calif.

      5/9/23 4:01:00 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual Meeting

      SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced a poster highlighting results from Phase 2 expansion cohorts of a Phase 1/2 dose escalation and expansion trial with zotatifin in patients with ER+ Metastatic Breast Cancer has been selected for presentation at the American Society of Clinical Oncology ("ASCO") 2023 Annual Meeting. Following the presentation, eFFECTOR will host a conference call to discuss the data. The ASCO website indicates that abstracts will be released on May 25, 2023

      4/26/23 4:01:00 PM ET
      $EFTR
      Biotechnology: Pharmaceutical Preparations
      Health Care